Our findings demonstrated that IRF4‐mediated SOX9 induction in BCL2‐overexpressing DLBCL was associated with tumour progression, suggesting the potential therapeutic implication of the IRF4‒SOX9 signalling axis in this type of DLBCL. Here, BCL2 is linked to neoplasm.